- Home
- ACAD vs DXC Comparison
ACAD vs DXC Comparison
Compare ACAD & DXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- DXC
- Stock Information
- Founded
- ACAD 1993
- DXC 1959
- Country
- ACAD United States
- DXC United States
- Employees
- ACAD N/A
- DXC N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- DXC EDP Services
- Sector
- ACAD Health Care
- DXC Technology
- Exchange
- ACAD Nasdaq
- DXC Nasdaq
- Market Cap
- ACAD 2.8B
- DXC 3.3B
- IPO Year
- ACAD 2004
- DXC N/A
- Fundamental
- Price
- ACAD $16.61
- DXC $17.05
- Analyst Decision
- ACAD Buy
- DXC Hold
- Analyst Count
- ACAD 17
- DXC 7
- Target Price
- ACAD $24.00
- DXC $21.29
- AVG Volume (30 Days)
- ACAD 1.5M
- DXC 2.9M
- Earning Date
- ACAD 05-07-2025
- DXC 05-15-2025
- Dividend Yield
- ACAD N/A
- DXC N/A
- EPS Growth
- ACAD N/A
- DXC N/A
- EPS
- ACAD 1.36
- DXC N/A
- Revenue
- ACAD $957,797,000.00
- DXC $13,088,000,000.00
- Revenue This Year
- ACAD $13.07
- DXC N/A
- Revenue Next Year
- ACAD $9.97
- DXC N/A
- P/E Ratio
- ACAD $12.28
- DXC N/A
- Revenue Growth
- ACAD 31.85
- DXC N/A
- 52 Week Low
- ACAD $14.15
- DXC $14.79
- 52 Week High
- ACAD $20.68
- DXC $24.83
- Technical
- Relative Strength Index (RSI)
- ACAD 36.91
- DXC 39.83
- Support Level
- ACAD $16.86
- DXC $16.19
- Resistance Level
- ACAD $17.31
- DXC $17.57
- Average True Range (ATR)
- ACAD 0.51
- DXC 0.57
- MACD
- ACAD -0.00
- DXC 0.10
- Stochastic Oscillator
- ACAD 23.24
- DXC 51.50
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About DXC DXC Technology Company
DXC Technology Co is a vendor-independent IT services provider. The company's operating segment includes Global Business Services (GBS) and Global Infrastructure Services (GIS). It generates maximum revenue from the GIS segment. GIS offerings include Cloud and Security; IT Outsourcing and Modern Workplace. Geographically, it derives a majority of revenue from the Other Europe region.